Goldman Sachs
BHVN

Goldman Sachs’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Goldman Sachs’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,062,350
Closed -$161M – 6668
2022
Q3 		$161M Buy
1,062,350
+343,671
+48% +$50.9M 0.04% 473
2022
Q2 		$105M Buy
718,679
+345,694
+93% +$44.2M 0.03% 657
2022
Q1 		$44.2M Buy
372,985
+134,599
+56% +$16.8M 0.01% 1379
2021
Q4 		$32.9M Buy
238,386
+111,844
+88% +$14.2M 0.01% 1678
2021
Q3 		$17.6M Sell
126,542
-303,925
-71% -$37.9M ﹤0.01% 2190
2021
Q2 		$41.8M Buy
430,467
+126,951
+42% +$10.3M 0.01% 1419
2021
Q1 		$20.7M Sell
303,516
-215,362
-42% -$17.4M 0.01% 1900
2020
Q4 		$44.5M Buy
518,878
+52,229
+11% +$4.43M 0.01% 1207
2020
Q3 		$30.3M Buy
466,649
+40,932
+10% +$2.68M 0.01% 1401
2020
Q2 		$31.1M Buy
425,717
+15,327
+4% +$816K 0.01% 1325
2020
Q1 		$14M Sell
410,390
-167,920
-29% -$7.68M ﹤0.01% 1794
2019
Q4 		$31.5M Buy
578,310
+269,776
+87% +$13.4M 0.01% 1493
2019
Q3 		$12.9M Buy
308,534
+69,567
+29% +$2.94M ﹤0.01% 2146
2019
Q2 		$10.5M Sell
238,967
-25,209
-10% -$1.42M ﹤0.01% 2328
2019
Q1 		$13.6M Buy
264,176
+48,549
+23% +$2.1M ﹤0.01% 2183
2018
Q4 		$7.97M Buy
215,627
+163,893
+317% +$5.91M ﹤0.01% 2504
2018
Q3 		$1.94M Buy
51,734
+2,558
+5% +$94.1K ﹤0.01% 3632
2018
Q2 		$1.94M Buy
49,176
+13,076
+36% +$415K ﹤0.01% 3641
2018
Q1 		$930K Buy
36,100
+6,378
+21% +$191K ﹤0.01% 4103
2017
Q4 		$802K Buy
+29,722
New +$818K ﹤0.01% 4474

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Goldman Sachs's BHVN Position: Q4 2022 in Review

Goldman Sachs sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,062,350 shares — an estimated $161M sold.

Goldman Sachs first reported a position in BHVN in Q4 2017 and held it in 20 quarters. The position peaked at $161M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Goldman Sachs reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,062,350 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $161M.
  • Goldman Sachs first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 20 quarters.
  • Goldman Sachs's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $161M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.